Integrating MRI Imaging and Biomarkers for the Early Detection of Alzheimer's Disease through AI

Emine Bozkina

Master of Science in Artificial Intelligence

from the

University of Surrey

School of Computer Science and Electronic Engineering

Faculty of Engineering and Physical Sciences

University of Surrey

Guildford, Surrey, GU2 7XH, UK

September 2024

Supervised by: Prof. Miroslaw BOBER

DECLARATION of ORIGINALITY

I confirm that the project dissertation I am submitting is entirely my own work and that any material used from other sources has been clearly identified and properly acknowledged and referenced. In submitting this final version of my report to the JISC anti-plagiarism software resource, I confirm that my work does not contravene the university regulations on plagiarism as described in the Student Handbook. In so doing I also acknowledge that I may be held to account for any particular instances of uncited work detected by the JISC anti-plagiarism software, or as may be found by the project examiner or project organizer. I also understand that if an allegation of plagiarism is upheld via an Academic Misconduct Hearing, then I may forfeit any credit for this module or a more severe penalty may be agreed.

Dissertation Title:

Integrating MRI Imaging and Biomarkers for the Early Detection of Alzheimer's Disease through AI

Author Name:

Emine Bozkina _____ Date: 02/ 09/ 2024

Supervisor name: Prof. Miroslaw BOBER

WORD COUNT

Number of Pages: 36

Number of Words: 6493

ABSTRACT

Alzheimer's Disease, or AD, is a progressive neurological disorder marked by a steady decline in cognitive abilities, including memory loss and behavioral changes. It has a worldwide influence, affecting millions of people. While there have been advancements in understanding the fundamental causes of the condition, early detection remains a significant challenge. This is due to the fact that traditional diagnostic tests usually detect the disease only after significant brain damage has occurred. This dissertation presents a comprehensive system for accurately detecting and predicting the onset of Alzheimer's Disease in its initial phase. The strategy entails integrating contemporary artificial intelligence methodologies, such as Convolutional Neural Networks (CNN) and Long Short-Term Memory (LSTM) networks. The system employs many data sources such as MRI imaging, genetic information, clinical biomarkers, and cognitive testing. These data are obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The study showcases that the incorporation of many forms of data greatly improves the accuracy of diagnosis and allows for the prompt detection of modest neurodegenerative alterations before the occurrence of severe cognitive deterioration. The CNN model was utilized to assess MRI images, detecting structural anomalies, while the LSTM model analyzed sequential biomarker data to forecast the progression of illness within a designated timeframe.

This paper makes a noteworthy addition by creating a concise and unified model that combines Convolutional Neural Networks (CNN) with Long Short-Term Memory (LSTM) networks. This model serves as a comprehensive tool for detecting early indicators of Alzheimer's Disease and forecasting its future progression. Nevertheless, the research faced technological obstacles, including in the handling and processing of high-resolution MRI images. This task necessitated substantial computational resources and resulted in prolonged data processing durations. In order to tackle this issue, the images were resized to a smaller dimension, resulting in enhanced processing efficiency. However, this approach may have resulted in a loss in diagnostic accuracy to some extent.

The study highlights the limitations of the ADNI dataset, including issues related to sample bias and data variability, which may affect the relevance of the findings. Proposed future study areas are improving AI models by integrating larger datasets that track the progression of various biomarkers over time, and addressing memory limitations associated with handling massive volumes of data.

The proposed AI framework has the potential to be utilized not just for identifying and managing Alzheimer's Disease but also for other neurodegenerative conditions such as Parkinson's Disease and multiple sclerosis. This technology possesses the capacity to entirely revolutionize disease diagnostics and the capability to predict the progression of diseases. This will enable the development of customized treatment and support strategies that significantly enhance patient results. The dissertation concludes by highlighting the capacity of artificial intelligence (AI) to improve our understanding and management of Alzheimer's disease. Furthermore, it emphasizes the necessity for further research to tackle current limitations and expand the scope of these innovative diagnostic instruments.

TABLE OF CONTENTS

LIST of FIGURES

1 INTRODUCTION

1.1 Background

1.1.1 Overview of Alzheimer’s Disease

Alzheimer's Diseases is a degenerative neurological condition that worsens with time and is marked by a deterioration in cognitive function, loss of memory, and alterations in behavior. It is thepredominant cause of dementia in the elderly, responsible for 60-80% of dementia occurrences worldwide. The pathophysiology of Alzheimer's disease is characterized by the buildup of amyloid-betaplaques and tau tangles in the brain, resulting in neuronal death and shrinkage of the hippocampus and cortex areas. Although there have been notable advancements in comprehending the condition, AD is still incurable. The main focus of therapy approaches is on managing symptoms rather than modifying the disease itself [1].

Timely identification of Alzheimer's Disease is crucial as it enables prompt care, which can decelerate the advancement of symptoms and enhance the quality of life for patients. Conventional diagnostic approaches, such as clinical evaluation, neuropsychological examination, and basic imaging modalities, frequently identify the disease only after substantial brain injury has already place. Hence, there is an increasing demand for sophisticated diagnostic instruments capable of detecting Alzheimer's Disease at its initial phases, preferably prior to the manifestation of clinical symptoms [2].

1.1.2 Importance of Early Detection

The early identification of Alzheimer's Disease has numerous benefits. It offers patients the chance to engage in research trials, obtain prospective medications that can improve their disease, and make well-informed choices regarding their future healthcare. Furthermore, an early diagnosis can facilitate the creation of customized treatment strategies that are designed to address the unique requirements and progression patterns of each patient [3]. Given the diverse characteristics of Alzheimer's Diseases, it is crucial to consider that the speed at which the disease progresses and the effectiveness of treatment might differ greatly among patients [4].

Advancements in the field of medical imaging and biomarkers have recently provided new opportunities for the timely identification of Alzheimer's Diseases. Magnetic Resonance Imaging (MRI) enables the visualization of brain structure and function, making it possible to detect early neurodegenerative alterations [5]. Furthermore, biomarkers such as amyloid-beta, tau, and neurofilament light chain offer biological proof of the disease, even prior to the noticeable deterioration in cognitive function [6]. By using artificial intelligence (AI) and machine learning models, these tools have the capacity to transform the early identification of Alzheimer's disease by enhancing diagnostic precision and facilitating the forecasting of disease advancement [7].

1.2 Objectives

1.2.1 Research Questions

The primary goal of this project is to investigate the combination of MRI imaging and biomarkers for the early identification of Alzheimer's Disease using AI approaches. The study seeks to investigate the following research enquiries:

What are the most effective methods for integrating MRI imaging with biomarkers to enhance the early identification of Alzheimer's Diseases?

Which AI models are the most efficient for evaluating MRI and biomarker data in the context of Alzheimer's Disease?

What are the applications of AI models in predicting the temporal course of Alzheimer's Diseases?

What are the constraints and difficulties associated with utilizing AI for the early identification of Alzheimer's Diseases?

1.2.2 Hypotheses

The research questions have led to the establishment of the following hypotheses:

Hypothesis 1: The combination of MRI imaging and biomarkers, evaluated using AI models, will greatly enhance the precision of early identification of Alzheimer's Disease in comparison to conventional diagnostic techniques [8].

Hypothesis 2: Convolutional Neural Networks (CNN) are efficacious in processing MRI data to detect structural brain alterations linked to Alzheimer's Disease[9].

Hypothesis 3: Long Short-Term Memory (LSTM) networks have the capability to effectively model and forecast the advancement of Alzheimer's Disease through the analysis of temporal biomarker data [10].

Hypothesis 4: The integration of CNN and LSTM models into a compact framework will yield a comprehensive tool capable of recognizing early indicators of Alzheimer's Disease and forecasting its advancement[11].

1.3 Scope of the Dissertation

This dissertation centers on the utilization of sophisticated artificial intelligence techniques, specifically Convolutional Neural Network (CNN) and Long Short-Term Memory (LSTM) models, to combine MRI imaging and biomarker data to diagnose Alzheimer's Disease at an early stage. The research involves gathering, organizing, and analyzing data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a global research project that provides a comprehensive dataset of genetic, clinical, and imaging

data for the study of Alzheimer's disease. [12].

1.3.1 MRI Imaging Focus

MRI imaging is crucial in this research as it offers comprehensive data on brain anatomy and function, enabling the early detection of Alzheimer's Disease. The study entails the process of downsizing and normalizing MRI images to ensure their suitability for analysis by AI models. The project seeks to utilize Convolutional Neural Networks (CNNs) to detect patterns in MRI data that are suggestive of initial neurodegenerative alterations linked to Alzheimer's Disease. This strategy utilizes the superior spatial resolution of MRI to identify minor alterations in brain structure that may not be detectable using alternative diagnostic techniques [13].

1.3.2 Biomarkers Focus

Biomarkers, such as genetic markers and proteins like amyloid-beta and tau, offer molecular proof of Alzheimer's Disease. This dissertation investigates the function of these biomarkers in the timely identification of Alzheimer's disease and explores how they might be used with MRI data to enhance the precision of diagnosis [14]. The study entails categorizing genetic and clinical biomarker data according to individual illness profiles and correlating this data with related MRI pictures. AI models are anticipated to improve the detection and monitoring of Alzheimer's Disease by integrating multimodal data [15].

1.3.3 AI Integration

The primary focus of this research is to create and utilize AI models for the analysis of combined MRI and biomarker data. Convolutional neural networks (CNNs) are used to interpret and analyze MRI images, specifically to detect and identify structural anomalies that are linked to Alzheimer's Disease [16]. LSTM networks, in contrast, are employed to analyze sequential patterns of biomarker data, facilitating the forecasting of illness progression over a period of time [17]. The project intends to develop a robust tool for recognizing early indications of Alzheimer's and predicting its future progression by incorporating these models into a concise framework [18]. The integrated model is trained and validated using the ADNI dataset. Its performance is assessed using multiple measures, such as loss, accuracy, AUC, and ROC curves [19].

The dissertation also includes a pragmatic implementation of the model, wherein a subset of cases from the dataset are randomly chosen and examined to juxtapose the model's forecasts with the real disease outcomes. This research provides vital insights into the accuracy of the model and its potential utility in a clinical environment. The outcomes of these comparisons, in conjunction with the model's performance feedback, are utilized to enhance the AI framework and provide avenues for future research [20].

2. LITERATURE REVIEW

2.1 Overview of Alzheimer's Disease

2.1.1 Alzheimer's Disease Pathophysiology

Alzheimer's disease (AD) is a degenerative neurological condition characterized by the buildup of amyloid-beta plaques and tau protein tangles in the brain. The indicated pathogenic properties result in a reduction in synaptic activity, the demise of neurons, and a notable shrinkage in brain size, particularly in crucial regions like the hippocampus and cortex, which are vital for memory and cognitive functioning. The development of the disease known as Alzheimer's (AD) is influenced by intricate molecular and cellular processes that include oxidative stress, mitochondrial malfunction, and inflammatory reactions. Genetic factors are highly influential in the formation and advancement of the disease, since alterations in genes like APP, PSEN1, and PSEN2 have been associated with the occurrence of early-onset familial Alzheimer's Disease. The APOE ε4 allele is the primary genetic factor that enhances the probability of acquiring late-onset Alzheimer's disease (AD) and influences the progression of the disease.[9].

2.1.2 Current Diagnostic Approaches

The diagnosis of Alzheimer's Disease typically depends on a mix of clinical evaluations and cognitive assessments, such as the MMSE (Mini-Mental State Examination) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). These tests assist in evaluating the extent of cognitive impairment and deterioration in memory in patients. However, due to the similarity of symptoms between this form of dementia and other types, depending simply on these methods often lacks the required accuracy to provide a definitive diagnosis. Therefore, neuroimaging techniques, such as MRI, have become essential for diagnosing AD as they reveal structural changes in the brain, such as hippocampal atrophy, which is a defining trait of the disease. Furthermore, the application of cerebrospinal fluid (CSF) biomarkers, such as decreased amyloid-beta levels and elevated tau proteins, provides a more accurate diagnosis and can even identify the disease in its preclinical stages. Utilizing PET imaging to detect amyloid and tau is essential for distinguishing Alzheimer's disease (AD) from other types of dementia, hence assisting in the selection of treatment choices and care plans. [12].

2.2 MRI Imaging in Alzheimer's Detection

2.2.1 Historical Development of MRI

Magnetic Resonance Imaging (MRI) has shown substantial progress since its inception in the 1970s and has become a fundamental tool in the diagnosis and examination of neurodegenerative conditions such as Alzheimer's Disease. Initial MRI studies primarily examined macroscopic structural alterations, such

as brain shrinkage, that are particularly noticeable during the advanced phases of Alzheimer's disease (AD). With the advancement of technology, MRI has developed the ability to identify even the most modest structural alterations in the brain that arise during the initial phases of the disease. MRI has become a crucial tool in the early identification and monitoring of Alzheimer's disease due to its capacity to visualize and quantify the volume of specific brain regions, such as the hippocampus and entorhinal cortex. The advancement of functional MRI (fMRI) and other sophisticated techniques, such as Diffusion Tensor Imaging (DTI), has significantly improved the capacity to investigate brain function and connection. This has allowed for a deeper understanding of how Alzheimer's Disease (AD) impacts neural networks over a period [18].

2.2.2 MRI Techniques Used in Alzheimer's Disease

Structural MRI is mainly employed in the study of Alzheimer's Disease to evaluate brain atrophy, namely in areas that are known to be impacted early in the disease, such as the hippocampus, entorhinal cortex, and posterior cingulate gyrus. These regions exhibit substantial decreases in volume as the disease advances, which is associated with the extent of cognitive deterioration. MRI techniques that are more advanced have increased the usefulness of MRI beyond just imaging the structure. Diffusion Tensor Imaging (DTI) is a technique that measures the movement of water molecules along axonal fibres to assess the integrity of white matter. This method can detect early indications of neurodegeneration in Alzheimer's disease (AD). Arterial Spin Labelling (ASL) is a sophisticated MRI technique used to quantify cerebral blood flow, which helps to identify and understand the reduced blood supply commonly seen in Alzheimer's disease (AD). Functional MRI (fMRI) is employed for investigating modifications in brain activity by detecting variations in blood oxygen levels, which can unveil changes in functional connectivity within brain networks impacted by AD. By combining modern techniques with structural imaging, a comprehensive strategy to detecting and monitoring Alzheimer's Disease is achieved. This approach allows for earlier and more accurate therapies [18].

2.3 Biomarkers in Alzheimer's Disease

2.3.1 Genetic Biomarkers

Genetic markers play a crucial role in identifying individuals who have a higher vulnerability to Alzheimer's condition and in comprehending the fundamental factors contributing to the condition. The APOE ε4 allele is the main genetic determinant that raises the likelihood of acquiring late-onset Alzheimer's disease. It is linked to an increased probability of acquiring the illness and an earlier manifestation of symptoms. Individuals who possess one or two copies of the APOE ε4 allele have a much higher risk compared to individuals who possess the more prevalent APOE ε3 variant. Furthermore, there is a correlation between genetic mutations in the amyloid precursor protein (APP) gene, as well as the presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes, and the occurrence of early-onset familial Alzheimer's Disease. These genetic abnormalities cause incorrect handling of the amyloid-beta protein,

resulting in the buildup of plaques in the brain. The accumulation of plaques is a characteristic feature of Alzheimer's disease. The discovery of these genetic markers has not only enhanced our comprehension of the fundamental causes of Alzheimer's disease but also unveiled novel prospects for the creation of focused medicines and techniques for early intervention. [13].

2.3.2 Clinical Biomarkers

The diagnosis and monitoring of Alzheimer's Disease mainly depend on clinical biomarkers, namely those found in cerebrospinal fluid (CSF). The biomarkers commonly used are amyloid-beta (Aβ42) and tau proteins (total tau and phosphorylated tau), which properly reflect the essential clinical features of Alzheimer's disease (AD). Reduced levels of Aβ42 in the cerebrospinal fluid (CSF) indicate the existence of amyloid plaque accumulation in the brain, whereas elevated levels of total tau and phosphorylated tau are linked to the development of neurofibrillary tangles and harm to neurons. Biomarkers can be detected long in advance of the manifestation of clinical symptoms, making them highly effective tools for early diagnosis. PET (positron emission tomography) imaging of amyloid and tau allows for the observation of aberrant changes in living animals, providing additional data. These biomarkers are crucial elements of the diagnostic criteria for AD and are used to assess the effectiveness of therapy interventions in clinical studies. [12].

2.4 Integration of MRI and Biomarkers

2.4.1 Combined Diagnostic Approaches

The combination of MRI and biomarkers has significantly transformed the diagnosis and treatment of Alzheimer's Disease by offering a more thorough evaluation of the condition. The accuracy of early diagnosis can be improved by combining structural MRI with CSF biomarkers, as this allows for the correlation of imaging findings with molecular signs of disease pathology. For instance, magnetic resonance imaging (MRI) can identify the shrinkage of the hippocampus, while cerebrospinal fluid (CSF) biomarkers offer proof of the accumulation of amyloid-beta and the presence of tau-related abnormalities. This integrated methodology is especially valuable in differentiating Alzheimer's disease from other types of dementia, which may exhibit same clinical symptoms but possess distinct underlying pathology. By employing these techniques in conjunction, medical professionals can enhance diagnostic precision, forecast the advancement of diseases, and customize treatment strategies to suit the specific requirements of patients. [18].

2.4.2 Advantages of Multimodal Imaging

Utilizing many imaging techniques such as MRI, PET, and CT scans, multimodal imaging has numerous benefits in the examination and treatment of Alzheimer's Disease. Through the integration of many modalities, researchers and doctors can acquire a more comprehensive comprehension of the disease's impact on the brain. Structural MRI can be utilized to evaluate brain atrophy, whereas PET imaging can offer insights into amyloid and tau accumulation. By integrating various modalities, a more thorough

evaluation of the disease can be achieved, resulting in the ability to detect it at an earlier stage, accurately track its progression, and effectively assess the effectiveness of treatment. This method also aids in the identification of subtypes of AD, which may exhibit distinct responses to therapies, thereby facilitating the development of better tailored medicine [18].

2.5 AI in Medical Imaging and Disease Prediction

2.5.1 AI Techniques in MRI Analysis

Artificial intelligence (AI) has become an effective tool in analyzing MRI data, with the potential to greatly improve the early detection and diagnosis of Alzheimer's Disease. Artificial intelligence methods, namely machine learning algorithms such as Convolutional Neural Networks (CNNs), have the ability to analyze extensive amounts of MRI data in order to detect patterns and characteristics related to Alzheimer's disease that may not be noticeable to humans. These algorithms possess the ability to autonomously divide brain areas, measure the extent of shrinkage, and monitor alterations over a period, rendering them extremely relevant in both clinical and research environments. Furthermore, AI models can undergo training using extensive datasets to enhance their precision and ability to apply to diverse populations and imaging techniques [9].

2.5.2 Machine Learning Models in Biomarker Analysis

Machine learning methods are being used to analyze biomarker data in Alzheimer's Disease. These models are capable of processing intricate datasets, incorporating information from many sources such as CSF biomarkers, genetic data, and neuroimaging. Through the analysis of these multimodal information, machine learning algorithms can detect patterns that forecast the beginning and progression of diseases, enabling earlier intervention and the implementation of more tailored treatment approaches. Machine learning algorithms can be employed to predict the advancement of Alzheimer's Disease in individuals with Mild Cognitive Impairment (MCI) by examining their biomarker profiles. Predictive models are gaining significance in the age of precision medicine, which aims to customize therapies based on the unique attributes of each patient. [17].

3 METHODOLOGIES

3.1 Data Acquisition from ADNI

3.1.1 Overview of ADNI Dataset

The Alzheimer's Disorder Neuroimaging Initiative (ADNI) is a renowned research project that commenced in 2004. The primary objective is to gather comprehensive data on various cognitive stages, including MRI, PET imaging, cerebrospinal fluid (CSF) biomarkers, genetic data, and neuropsychological tests. The ADNI dataset is essential for improving our understanding of the progression of Alzheimer's Disease (AD) and developing predictive models that can assist in early detection and intervention[15].

3.1.2 Ethical Considerations and Data Use

ADNI operates under rigorous ethical standards to protect the privacy and rights of its participants. Informed consent is obtained from all participants, and the data is anonymized to ensure confidentiality. These ethical practices are critical in maintaining the integrity of the research and ensuring that the data is used in a manner that maximizes scientific value while minimizing potential risks to participants.

3.2 Data Preparation and Preprocessing

3.2.1 MRI Image Preprocessing

MRI images from the ADNI dataset undergo extensive preprocessing to ensure they are standardized and suitable for analysis. Key preprocessing steps include:

Spatial Normalization: Each MRI image is aligned to a standard anatomical template, which corrects for differences in brain size and orientation among participants. This normalization is crucial for accurate cross-subject comparisons and is a fundamental step in group-level analyses [18].

Bias Field Correction: MRI images often exhibit intensity inhomogeneities due to scanner-related artifacts. Bias field correction is applied to mitigate these artifacts, ensuring that the intensity values reflect true anatomical structures rather than being distorted by technical factors [5].

Skull stripping and tissue segmentation involve the removal of non-brain tissues from the pictures and the division of the brain into different types of tissues, such as grey matter, white matter, and cerebrospinal fluid. This segmentation allows for detailed volumetric analyses, whichare essential for understanding the structural changes associated with Alzheimer’s Disease [17].

3.2.2 Biomarker Data Normalization

Biomarker data, particularly from cerebrospinal fluid (CSF), is critical for understanding the biochemical underpinnings of Alzheimer’s Disease. To ensure consistency across different collection sites and assays, several normalization techniques are applied:

Standardization: Biomarker values are standardized to have a mean of zero and a deviation from the mean of one. This process is essential for making accurate comparisons between samples, particularly when integrating data from multiple sources [14].

Log Transformation: Given the skewed nature of biomarker data distributions, a log transformation is often applied to normalize the data. This transformation makes the data more suitable for statistical analysis and machine learning models, improving the robustness of the findings [19].

Batch Effect Correction: Variability in the data introduced by differences in sample processing or collection protocols is addressed through batch effect correction. This step ensures that any observed differences in biomarker levels are due to biological variability rather than technical inconsistencies [20].

3.3 MRI Image Resizing and Normalization

3.3.1 Image Resizing Techniques

To prepare MRI images for analysis using convolutional neural networks (CNNs), it is necessary to resize the images to a uniform dimension. Resizing is performed using interpolation techniques, such as bicubic interpolation, which helps preserve the anatomical integrity of the images while standardizing them for input into CNN models. This step is critical to ensure that the models can process the images efficiently and consistently, regardless of their original resolution or size [18].

Code Implementation:

```
def load_and_resize_mri_image(image_path, target_shape=(64, 64, 64)):
    img = nib.load(image_path).get_fdata()
    zoom_factors = [t/s for t, s in zip(target_shape, img.shape)]
    img_resized = zoom(img, zoom_factors, order=1)
    img_resized = np.expand_dims(img_resized, axis=-1)
    img_resized = img_resized / np.max(img_resized)
    return img_resized
```

Figure 3.1- Image Resizing

The function that can be seen in Figure 3.1 loads MRI images and resizes them to a uniform shape, preparing them for input into a CNN model.

3.3.2 Normalization of Image Data

Normalization of MRI images involve scaling the intensity values across all images to ensure consistency, regardless of variations in scanner settings or acquisition protocols. This process reduces variability that could otherwise confound the analysis and model training, enhancing the reliability of the results. By scaling the intensity values, the images become more comparable, facilitating the accurate detection of disease-related changes in brain structures [18].

3.4 Dataset Matching and Integration

3.4.1 Matching MRI with Clinical Data

A critical aspect of this research is the precise matching of MRI scans with corresponding clinical data, including demographic information, cognitive assessments, and diagnostic labels. This matching process is vital for creating a dataset that accurately reflects the patient's condition and enables the tracking of disease progression over time. Furthermore, it facilitates the linkage between imaging biomarkers and clinical results, so offering a thorough understanding of the relationship between structural alterations in the brain and cognitive decline.

Code Implementation:

```
# Function to create image path
def create_image_path(image_id, subject, acq_date):
    formatted_date = pd.to_datetime(acq_date).strftime('%Y-%m-%d')
    matched_files = [file for file in mri_images_full_paths if image_id in file or (subject in file and formatted_date in file)]
    return matched_files[0] if matched_files else None
```

Figure 3.2- Image Path

The function that can be seen in Figure 3.2 snippet creates paths for MRI images based on subject IDs and acquisition dates, matching them with clinical data in the dataset.

3.4.2 Integration of Multimodal Data

To enhance the predictive accuracy of models for Alzheimer's Disease, it is essential to integrate MRI data with other types of data, such as PET imaging, CSF biomarkers, and genetic information. This multimodal data integration leverages the strengths of each modality, providing a more holistic view of the disease. Advanced machine learning techniques, including data fusion methods, are employed to combine these diverse datasets into a cohesive framework that supports comprehensive analysis and improves diagnostic accuracy.

3.5 CNN Model for MRI Analysis

3.5.1 Model Architecture

The architecture of the convolutional neural network (CNN) model for MRI analysis is specifically developed to extract and acquire intricate characteristics from the pictures. The architecture generally has multiple layers, such as convolutional layers for identifying patterns in the images, pooling layers for reducing data dimensionality, and fully connected layers for combining these features to provide a final prediction. This architecture is specifically designed to efficiently process the extensive number of dimensions and intricate nature of MRI data. As a result, it is highly suitable for accurately detecting small structural alterations in the brain that are linked to Alzheimer's Disease.

Code Implementation:

```
# 3. CNN model (for MRI images)
cnn_input = Input(shape=(64, 64, 64, 1))
cnn_output = Conv3D(16, (3, 3, 3), activation='relu')(cnn_input)
cnn_output = BatchNormalization()(cnn_output)
cnn_output = MaxPooling3D(pool_size=(2, 2, 2))(cnn_output)
cnn_output = Conv3D(32, (3, 3, 3), activation='relu')(cnn_output)
cnn_output = BatchNormalization()(cnn_output)
cnn_output = MaxPooling3D(pool_size=(2, 2, 2))(cnn_output)
cnn_output = Conv3D(64, (3, 3, 3), activation='relu')(cnn_output)
cnn_output = BatchNormalization()(cnn_output)
cnn_output = MaxPooling3D(pool_size=(2, 2, 2))(cnn_output)
cnn_output = Flatten()(cnn_output)
cnn_output = Dense(256, activation='relu')(cnn_output)
cnn_output = BatchNormalization()(cnn_output)
```

Figure 3.3- CNN Model

The function that can be seen in Figure 3.3 implements a CNN architecture designed for processing MRI images, including convolutional, pooling, and fully connected layers.

3.6 LSTM Model for Disease Progression Prediction

3.6.1 Time-Series Data Preparation

Long Short-Term Memory (LSTM) models are particularly well suited for analysing time-series data, making them ideal for predicting the progression of Alzheimer's Disease. Time-series data preparation involves structuring sequential data, such as longitudinal biomarker readings, cognitive test scores, and repeated MRI measurements, into sequences that the LSTM model can process. This preparation is crucial for enabling the model to learn temporal patterns that predict disease progression, providing valuable insights into how Alzheimer's Disease evolves over time [21].

Code Implementation:

```
# 4. RNN model (for clinical data) -
rnn_input = Input(shape=(X_train.shape[1], 1))
rnn_output = LSTM(25, return_sequences=True)(rnn_input)
rnn_output = LSTM(25, return_sequences=True)(rnn_output)
rnn_output = LSTM(25)(rnn_output)
```

Figure 3.4- LSTM Model

This snippet that can be seen in Figure 3.4, sets up an LSTM model designed to process and analyse temporal sequences of clinical data.

3.7 Compact Model Development and Integration

3.7.1 Combining CNN and LSTM Models

To create a more robust predictive tool, the CNN and LSTM models are integrated into a compact model that leverages the strengths of both approaches. The CNN component processes spatial features from MRI images, while the LSTM component analyses temporal sequences from longitudinal data. By employing this integrated methodology, the model's capacity to identify initial indications of Alzheimer's Disease and forecast its advancement over a period of time is improved.

Code Implementation:

```
# 5. Combine CNN and RNN layers
combined = concatenate([cnn_output, rnn_output])

# 6. Fully connected layers -
final_output = Dense(128, activation='relu')(combined)
final_output = BatchNormalization()(final_output)
final_output = Dense(len(label_encoder.classes_), activation='softmax')(final_output)

# 7. Create the model
integrated_model = Model(inputs=[cnn_input, rnn_input], outputs=final_output)
optimizer = Adam(learning_rate=0.001)
integrated_model.compile(optimizer=optimizer, loss='categorical_crossentropy', metrics=['accuracy'])
integrated_model.summary()
```

Figure 3.5- Combine Model

This code that can be seen in Figure 3.5, combines the CNN and LSTM models into a single integrated framework, ready for training and evaluation.

3.7.2 Model Integration Strategies

Integrating the CNN and LSTM models involves developing strategies that allow these two components to work together effectively. Typically, the features extracted by the CNN are fed into the LSTM model, enabling the integrated model to analyze both spatial and temporal data. This integration requires careful tuning of the hyperparameters for both models to optimize their combined performance. The result is a model that can provide a more holistic view of Alzheimer's Disease, offering improved diagnostic and prognostic capabilities.

3.7.3 Final Model Evaluation

The final integrated model is rigorously evaluated on a test dataset to ensure its overall effectiveness and reliability. The model's success in forecasting the course of Alzheimer's Disease is measured using performance metrics like as accuracy, precision, recall, F1-score, and AUC-ROC. Additionally, comparisons are made with standalone CNN and LSTM models to highlight thebenefits of the integrated approach. This evaluation is critical in demonstrating the model's robustness and generalizability, ensuring it can be reliably applied in clinical settings [23].

Code Implementation:

```
y_pred = integrated_model.predict([X_test_mri, X_test_rnn]).argmax(axis=1)
y_true = y_test.argmax(axis=1)
cm = confusion_matrix(y_true, y_pred)

plt.figure(figsize=(8, 6))
sns.heatmap(cm, annot=True, fmt='d', cmap='Blues', xticklabels=label_encoder.classes_, yticklabels=label_encoder.classes_)
plt.title('Confusion Matrix')
plt.ylabel('True Label')
plt.xlabel('Predicted Label')
plt.show()
```

Figure 3.6- Confusion Matrix

This code that can be seen in Figure 3.6, snippet demonstrates the process of evaluating the model's performance using various metrics, including accuracy and confusion matrix visualization.

3.8 Model Training and Validation

3.8.1 Training Strategies

The CNN-LSTM model undergoes staged training, beginning with the individual pre-training of each component. The Convolutional Neural Network (CNN) is trained on Magnetic Resonance Imaging (MRI) pictures to acquire knowledge about spatial characteristics, whereas the Long Short-Term Memory (LSTM) is trained using time-series data to detect and understand temporal patterns. Following the pre-training phase, the models are jointly fine-tuned using the combined dataset, enabling them to acquire additional characteristics that improve their collective performance. Regularization approaches, such as dropout and early stopping, are utilized to mitigate overfitting, hence ensuring that the model exhibits good generalization performance on unseen data. [19].

Code Implementation:

```
# 9. Model Training
model_checkpoint = ModelCheckpoint('best_model.h5', save_best_only=True, monitor='val_loss')

integrated_history = integrated_model.fit(
    [X_train_mri, X_train_rnn],
    y_train,
    epochs=30,
    batch_size=16,
    validation_data=([X_test_mri, X_test_rnn], y_test),
    class_weight=class_weights_dict,
    callbacks=[model_checkpoint]
)
```

Figure 3.7- Model Training

This code, which can be seen in Figure 3.7 snippet, shows the training process of the model.

3.8.2 Cross-Validation Techniques

Cross-validating, specifically k-fold cross-validation, is employed to guarantee the model's resilience and capacity to apply to new data. This approach involves partitioning the dataset into approximately 50 subsets. The model is then trained and validated iteratively, with each iteration using a different subset for validation and the remaining subsets for training. This technique provides a reliable evaluation of the model's performance and helps in choosing the optimal model configuration.

3.9 Performance Metrics: Loss, Accuracy, AUC & ROC

3.9.1 Loss and Accuracy Analysis

Loss and accuracy are essential parameters for assessing the performance of the CNN-LSTM model during both the training and testing stages. Loss quantifies the discrepancy between the model's predictions and the real outcomes, providing guidance for the optimization process. Cross-entropy loss is frequently employed for classification jobs. Accuracy is a metric that quantifies the proportion of accurate predictions made by the model in relation to the overall number of predictions. Tracking both the loss and accuracy during the training process aids in optimizing the model, guaranteeing effective learning and strong generalization[19].

Code Implementation:

```
# Plot training & validation accuracy and loss values
plt.figure(figsize=(12, 6))
plt.subplot(1, 2, 1)
plt.plot(loaded_history['accuracy'], label='Train Accuracy')
plt.plot(loaded_history['val_accuracy'], label='Validation Accuracy')
plt.title('Model Accuracy Over Epochs')
plt.ylabel('Accuracy')
plt.xlabel('Epoch')
plt.legend(loc='upper left')

plt.subplot(1, 2, 2)
plt.plot(loaded_history['loss'], label='Train Loss')
plt.plot(loaded_history['val_loss'], label='Validation Loss')
plt.title('Model Loss Over Epochs')
plt.ylabel('Loss')
plt.xlabel('Epoch')
plt.legend(loc='upper left')
plt.show()
```

Figure 3.8- Plot Training & Validation Accuracy

This code, which can be seen in Figure 3.8 snippet, shows the Training and Validation Rates graphically.

3.9.2 AUC & ROC Curve Interpretation

Both the Receiver Operating Characteristic (ROC) curve and the Area Under the Curve (AUC) are essential metrics for assessing how well the CNN-LSTM model performs, particularly when it comes to differentiating between classes like Alzheimer's disease and healthy controls. The ROC curve demonstrates the correlation between the true positive rate and the false positive rate at various threshold settings, providing a visual representation of the model's ability to differentiate between classes. The Area Under the Curve (AUC) summarizes the data represented by the curve into a singular numerical value. A greater AUC signifies superior overall performance. A model with an AUC value near to 1.0 is regarded as having exceptional discriminatory ability, making these measures crucial for evaluating the model's usefulness in clinical contexts. [20].

Code Implementation:

```
# Plot the ROC curve
plt.figure()
plt.plot(fpr, tpr, color='darkorange', lw=2, label='ROC Curve (area = %0.2f)' % roc_auc)
plt.plot([0, 1], [0, 1], color='navy', lw=2, linestyle='--')
plt.xlim([0.0, 1.0])
plt.ylim([0.0, 1.0])
plt.xlabel('False Positive Rate')
plt.ylabel('True Positive Rate')
plt.title('Receiver Operating Characteristic (ROC)')
plt.legend(loc="lower right")
plt.show()
```

Figure 3.9- Plot The ROC Curve

This complements the model training, validation and performance evaluation that can be seen in Figure 3.9 and provides a comprehensive framework for early detection and progression prediction of Alzheimer's Disease using an integrated CNN-LSTM model.

4. RESULTS AND DISCUSSION

4.1 Model Performance Evaluation

In this study, the performance of an artificial intelligence model developed for early diagnosis of Alzheimer's disease has been evaluated using various statistical metrics and analytical methods. The model's overall capability has been assessed in terms of both diagnostic accuracy and its ability to predict disease progression.

4.1.1 Accuracy and Loss Trends

The performance of the model during training and validation phases showed significant improvements

in training accuracy over time. However, validation accuracy exhibited fluctuations, which could indicate that the model has overfitted to the training set and may not generalize well to new, unseen data. These fluctuations suggest that there may need to be adjustments in the model's complexity and learning rate to enhance its generalization capabilities.



Figure 4.1- Training & Validation Charts

This graph provides a comprehensive presentation for validation and performance evaluation, which can be seen in Figure 4.1

4.1.2 AUC and ROC Curve Analysis

The analysis of the ROC curve and the calculation of the AUC value, which stood at 0.84, demonstrates that the model has a strong ability to distinguish between individuals with Alzheimer's disease and healthy controls. Nevertheless, the analysis also highlighted the necessity for improvements in reducing the false positive rate, which would enhance the model’s diagnostic precision. As it can be seen in Figure

4.2 , The true positive rate and false positive rate can be determined by conducting a test and analyzing the receiver operating characteristic (ROC) curve and area under the curve (AUC).



Figure 4.2- ROC Curve

4.2 Comparative Analysis of Disease Progression Predictions

4.2.1 Predicted vs. Actual Disease Progression

When comparing the model's predictions with actual clinical data, it was found that the model accurately predicted disease progression in most cases. However, there were instances where the predictions did not align with the actual disease outcomes, indicating that further training with an expanded dataset might be necessary to enhance the model's predictive accuracy.

4.2.2 Case Studies

Detailed case studies have been conducted to examine the accuracy of the model's predictions and to understand the potential reasons behind any incorrect predictions. These case studies have been instrumental in identifying which features the model is more or less sensitive to, aiding in refining the model's predictive capabilities.

4.3 Case Study: Testing with Randomly Selected Data

4.3.1 Selection Criteria

Tests conducted using randomly selected datasets have served as a crucial method for assessing the general applicability and robustness of the model. These tests have measured the model's effectiveness across individuals with varying demographic characteristics and stages of the disease.



Figure 4.3- MRI image (Patient 1)




```
--- MRI Data ---
Ventricles: 107226.0
Hippocampus: 6521.0
WholeBrain: 1178280.0
Entorhinal: 3194.0
Fusiform: 18403.0
MidTemp: 22144.0
ICV: 1977790.0

--- Biomarker Data ---
ABETA: 1700.0
TAU: 79.0
PTAU: 7.0
FDG: 1.18059
PIB: 1.85
AV45: 1.1068
FBB: 1.054

--- Genetic Data ---
APOE4: 1.0

--- Clinical Data ---
AGE: 71.6
PTGENDER: Male
PTEDUCAT: 20
PTETHCAT: Not Hisp/Latino
PTRACCAT: White
PTMARRY: Married

Actual Diagnosis (BL): LMCI

--- Predicted Disease Progression ---
  VISCODE Predicted Diagnosis
0      bl                LMCI
1     m06                LMCI
2     m12                LMCI
3     m24                LMCI
```

Figure 4.4- MRI image (Patient 2)




```
--- MRI Data ---
Ventricles: 25402.0
Hippocampus: 6872.0
WholeBrain: 1002580.0
Entorhinal: 3600.5
Fusiform: 17372.0
MidTemp: 19458.0
ICV: 1528630.0

--- Biomarker Data ---
ABETA: 1700.0
TAU: 79.0
PTAU: 7.0
FDG: 1.25982
PIB: 2.06
AV45: 1.1068
FBB: 1.054

--- Genetic Data ---
APOE4: 1.0

--- Clinical Data ---
AGE: 72.4
PTGENDER: Male
PTEDUCAT: 14
PTETHCAT: Not Hisp/Latino
PTRACCAT: White
PTMARRY: Married

Actual Diagnosis (BL): LMCI

--- Predicted Disease Progression ---
  VISCODE Predicted Diagnosis
0      bl                LMCI
1     m06                LMCI
2     m12                LMCI
3     m24                LMCI
--------------------------------------------------------------------------------
```

Figure 4.5- MRI image (Patient 3)

Figure 4.3a., Figure 4.3b., Figure 4.3 c. These Figures were estimated with the data of 3 different people.

4.3.2 Detailed Analysis of Case Studies

In this section, detailed analyses of selected case studies have provided deep insights into the model's predictive success and errors. The results have explained why the model might fail or succeed under certain conditions, offering a comprehensive review of its performance.

4.4 Model Feedback and Error Analysis

4.4.1 Common Misclassifications

The model's most frequent misclassifications and the possible reasons behind these errors have been thoroughly examined. This analysis has been critical in identifying the weaknesses of the model and suggesting potential improvements.

4.4.2 Model Improvements

The planned improvements to enhance the model's performance have been discussed, including the integration of additional datasets, algorithm optimizations, and adjustments to the model's parameters. These enhancements are expected to significantly affect the model's overall effectiveness.

5 CONCLUSIONS

5.1 Summary of Findings

5.1.1 Key Contributions

This dissertation proposed a holistic methodology for the timely identification of Alzheimer's Disease (AD) by the utilization of sophisticated artificial intelligence (AI) methods. The study employed MRI, genetic, clinical biomarkers, and neuropsychological data acquired from the Alzheimer's Syndrome Neuroimaging Initiative (ADNI). The model was created by combining convolutional neural networks (CNN) and long short-term memory (LSTM) networks, resulting in a succinct model. This approach enabled accurate forecastingof illness progression, providing substantial enhancements compared to conventional diagnostic techniques.

5.1.2 Implications for Early Detection

The results emphasize the capacity of artificial intelligence (AI) to completely transform the early identification of Alzheimer's Disease. The created approach can detect mild neurodegenerative alterations before they progress into significant cognitive deterioration by incorporating multimodal data. Early identification allows for the implementation of intervention techniques that have the potential to decelerate the development of the disease and enhance patient outcomes.

5.2 Limitations of the Study

5.2.1 Technical Limitations

Although the study employed a novel methodology, it faced technical obstacles such as the intricacy of training the model and the requirement for significant processing resources. The accuracy of the model's predictions is heavily reliant on the caliber of the input data and the complexity of the preprocessing procedures. The huge file sizes of high-resolution MRI scans presented considerable technical difficulties, resulting in extended data processing durations that frequently lasted 4-5 days. In order to alleviate this issue, the MRI pictures were resized to dimensions of 64x64, resulting in decreased file sizes and processing durations. Nevertheless, the process of reducing the scale of the data led to a decrease in the level of intricacy, which could potentially have a negative effect on the effectiveness of the machine learning training. The analysis was hindered by the considerable coding required and the high dataset sizes, which had a negative impact on the pace and efficiency of the research.

5.2.2 Dataset Limitations

The ADNI dataset, while extensive, presents limitations in terms of variability and representation. Issues such as sample bias, underrepresentation of certain demographic groups, and variability in data quality across different collection sites may have impacted the generalizability of the findings. Additionally, the massive size of the dataset proved to be a challenge, as the available GPU resources were often insufficient, slowing down both research and project timelines. Moreover, not all data provided the necessary information, complicating the machine learning training phase and making it difficult to obtain relevant data.

5.3 Future Research Directions

5.3.1 Potential Enhancements

Subsequent investigations may prioritize the improvement of AI models in order to augment diagnostic precision. This may involve using advanced AI approaches, such as deep learning algorithms, which offer more sophisticated analysis of intricate data patterns. Creating a comprehensive dataset that combines biomarkers, clinical, genetic, and MRI data, together with imaging investigations, will greatly enhance machine learning training. By monitoring the fluctuations in this data over time, the model would be able to enhance its comprehension and forecasting of illness advancement. Furthermore, tackling memory-related problems linked to the processing of such extensive datasets would enhance the performance and efficiency of the model. Implementing advanced data preprocessing techniques to effectively handle variability could potentially enhance the robustness and reliability of model outcomes.

5.3.2 Broader Applications

This discovery has the potential to be applied not only to Alzheimer's Disease but also to other neurodegenerative conditions. Subsequent research endeavors may employ the integrated artificial intelligence framework to identify and forecast the advancement of ailments such as Parkinson's Disease and multiple sclerosis. Moreover, this methodology can be employed not only for the purpose of disease diagnosis but also for the anticipation of disease advancement, hence facilitating the creation of customized therapy and assistance strategies. Implementing such strategies has the potential to greatly enhance the overall well-being of individuals by effectively catering to their unique requirements as the disease progresses. In addition, broadening the dataset to encompass a greater variety of people could enhance the development of diagnostic and prognostic tools that are useful across a wide spectrum of diseases.

This research has demonstrated the considerable potential of utilizing integrated AI models for the timely identification and prediction of the advancement of Alzheimer's Disease. Despite the presence of obstacles, the ongoing development of artificial intelligence (AI) and machine learning, together with progress in neuroimaging and biomarker research, has the potential to greatly improve our comprehension and treatment of Alzheimer's disease (AD). Subsequent research should focus on overcoming the existing constraints and broadening the range of this study to encompass wider elements and applications in the management of neurodegenerative diseases.

REFERENCES

[1] Yao, Z., Wang, H., Yan, W., Wang, Z., Zhang, W., Wang, Z. and Zhang, G., 2023. Artificial intelligence-based diagnosis of Alzheimer's disease with brain MRI images. *European Journal of Radiology*, *165*, p.110934.

[2] Liu, X., Chen, K., Wu, T., Weidman, D., Lure, F. and Li, J., 2018. Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease. *Translational Research*, *194*, pp.56-67.

[3] Zhao, X., Ang, C.K.E., Acharya, U.R. and Cheong, K.H., 2021. Application of Artificial Intelligence techniques for the detection of Alzheimer's disease using structural MRI images. *Biocybernetics and Biomedical Engineering*, *41*(2), pp.456-473.

[4] Franciotti, R., Nardini, D., Russo, M., Onofrj, M., Sensi, S.L. and Alzheimer's Disease Neuroimaging Initiative, 2023. Comparison of machine learning-based approaches to predict the conversion to Alzheimer's disease from mild cognitive impairment. *Neuroscience*, *514*, pp.143-152.

[5] Reiman, E.M. and Jagust, W.J., 2012. Brain imaging in the study of Alzheimer's disease. *Neuroimage*, *61*(2), pp.505-516.

[6] MacQueen, G.M., Hassel, S., Arnott, S.R., Addington, J., Bowie, C.R., Bray, S.L., Davis, A.D., Downar, J., Foster, J.A., Frey, B.N. and Goldstein, B.I., 2019. The Canadian biomarker integration network in depression (CAN-BIND): magnetic resonance imaging protocols. *Journal of Psychiatry & Neuroscience: JPN*, *44*(4), p.223.

[7] Vrahatis, A.G., Skolariki, K., Krokidis, M.G., Lazaros, K., Exarchos, T.P. and Vlamos, P., 2023. Revolutionizing the early detection of Alzheimer's disease through non-invasive biomarkers: the role of artificial intelligence and deep learning. *Sensors*, *23*(9), p.4184.

[8] Yang, K. and Mohammed, E.A., 2020. A review of artificial intelligence technologies for early prediction of Alzheimer's disease. *arXiv preprint arXiv:2101.01781*.

[9] Vemuri, P. and Jack, C.R., 2010. Role of structural MRI in Alzheimer's disease. *Alzheimer's research & therapy*, *2*, pp.1-10.

[10] Sadegh-Zadeh, S.A., Fakhri, E., Bahrami, M., Bagheri, E., Khamsehashari, R., Noroozian, M. and Hajiyavand, A.M., 2023. An approach toward artificial intelligence Alzheimer's disease diagnosis using brain signals. *diagnostics*, *13*(3), p.477.

[11] Long, Z., Li, J., Fan, J., Li, B., Du, Y., Qiu, S., Miao, J., Chen, J., Yin, J. and Jing, B., 2023. Identifying Alzheimer's disease and mild cognitive impairment with atlas-based multi-modal metrics. *Frontiers in Aging Neuroscience*, *15*, p.1212275.

[12] Gunes, S., Aizawa, Y., Sugashi, T., Sugimoto, M. and Rodrigues, P.P., 2022. Biomarkers for Alzheimer's disease in the current state: a narrative review. *International journal of molecular sciences*, *23*(9), p.4962.

[13] Lin, R.H., Wang, C.C. and Tung, C.W., 2022. A machine learning classifier for predicting stable MCI patients using gene biomarkers. *International Journal of Environmental Research and Public Health*, *19*(8), p.4839.

[14] Escudero, J., Ifeachor, E., Zajicek, J.P., Green, C., Shearer, J. and Pearson, S., 2012. Machine learning-based method for personalized and cost-effective detection of Alzheimer's disease. *IEEE transactions on biomedical engineering*, *60*(1), pp.164-168.

[15] Jack Jr, C.R., Bernstein, M.A., Fox, N.C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P.J., L. Whitwell, J., Ward, C. and Dale, A.M., 2008. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. *Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine*, *27*(4), pp.685-691.

[16] Zhang, Y. and Wang, S., 2015. Detection of Alzheimer's disease by displacement field and machine learning. *PeerJ*, *3*, p.e1251.

[17] Radford, A., Kim, J.W., Hallacy, C., Ramesh, A., Goh, G., Agarwal, S., Sastry, G., Askell, A., Mishkin, P., Clark, J. and Krueger, G., 2021, July. Learning transferable visual models from natural language supervision. In *International conference on machine learning* (pp. 8748-8763). PMLR.

[18] Chandra, A., Dervenoulas, G., Politis, M. and Alzheimer's Disease Neuroimaging Initiative, 2019. Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment. *Journal of neurology*, *266*, pp.1293-1302.

[19] Fathi, S., Ahmadi, A., Dehnad, A., Almasi-Dooghaee, M., Sadegh, M. and Alzheimer's Disease Neuroimaging Initiative, 2024. A deep learning-based ensemble method for early diagnosis of Alzheimer's disease using MRI images. *Neuroinformatics*, *22*(1), pp.89-105.

[20] Lucignani, G. and Neri, E., 2019. Integration of imaging biomarkers into systems biomedicine: a renaissance for medical imaging. *Clinical and Translational Imaging*, *7*, pp.149-153.

[21] van der Haar, D., Moustafa, A., Warren, S.L., Alashwal, H. and van Zyl, T., 2023. An Alzheimer's disease category progression sub-grouping analysis using manifold learning on ADNI. *Scientific reports*, *13*(1), p.10483.

[22] Wang, C., Li, Y., Tsuboshita, Y., Sakurai, T., Goto, T., Yamaguchi, H., Yamashita, Y., Sekiguchi, A., Tachimori, H. and Alzheimer's Disease Neuroimaging Initiative http://orcid. org/0000-0001-5252-1965 Wang Caihua 7 http://orcid. org/0000-0003-2490-4867 Li Yuanzhong 7 http://orcid. org/0000-0002-

4814-8093 Goto Tsubasa 7, 2022. A high-generalizability machine learning framework for predicting the progression of Alzheimer's disease using limited data. *NPJ digital medicine*, *5*(1), p.43.

[23] Hatamikia, S., Nougaret, S., Panico, C., Avesani, G., Nero, C., Boldrini, L., Sala, E. and Woitek, R., 2023. Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers. *European Radiology Experimental*, *7*(1), p.50.

APPENDİX



Figure APPENDIX

The Figure APPEDDIX show the flowchart and logic the python code that is used for project.